Behavior and outcomes of 141 acquired lacrimal sac mucoceles treated via endoscopic dacryocystorhinostomy.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

International journal of ophthalmology Pub Date : 2025-02-18 eCollection Date: 2025-01-01 DOI:10.18240/ijo.2025.02.07

Ying-Jie Ma, Guang-Ming Zhou, Zhi-Rong Liu, Jin-Fei Wei, Xin-Yu Li, Bin Dong, Lin-Juan Wu, Wen-Can Wu, Bo Yu

{"title":"Behavior and outcomes of 141 acquired lacrimal sac mucoceles treated via endoscopic dacryocystorhinostomy.","authors":"Ying-Jie Ma, Guang-Ming Zhou, Zhi-Rong Liu, Jin-Fei Wei, Xin-Yu Li, Bin Dong, Lin-Juan Wu, Wen-Can Wu, Bo Yu","doi":"10.18240/ijo.2025.02.07","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the clinical profile of patients with acquired lacrimal sac mucocele (ALSM) and evaluate the efficacy of endoscopic dacryocystorhinostomy (En-DCR) for this condition.Methods: En-DCRs were performed on 141 patients with ALSM patients from January 2016 to March 2022. The clinical baseline information and magnetic resonance imaging (MRI) images were recorded and summarized. To assess the effectiveness of En-DCR therapy, both anatomical and functional success rate was assessed during a 12mo follow-up.Results: A total of 141 patients, with a mean age of 57.70±14.11y, were enrolled in this study. Majority of the patients were female (n=91; 64.54%) and all had unilateral disease. All patients had a previous history of epiphora and purulent secretion, and the duration from lacrimal duct obstruction to mucocele formation ranged from 6 to 120mo. MRI findings consistently revealed an enlarged sac diameter, fluid accumulation separated by a thin rim from adjacent tissues, which is indicative of lacrimal sac mucocele. En-DCR was performed with an anatomical success rate of 93.62% and a functional success rate of 81.56%.Conclusion: ALSM is more commonly seen in females and unilaterally. It is essentially a complication of lacrimal duct obstruction. MRI characteristics can be used for precise clinical diagnosis, while En-DCR emerges as an optimal therapy for this condition. Our results provide a comprehensive reference for the diagnosis and treatment of ALSM.","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 2","pages":"244-250"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754020/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.02.07","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate the clinical profile of patients with acquired lacrimal sac mucocele (ALSM) and evaluate the efficacy of endoscopic dacryocystorhinostomy (En-DCR) for this condition.

Methods: En-DCRs were performed on 141 patients with ALSM patients from January 2016 to March 2022. The clinical baseline information and magnetic resonance imaging (MRI) images were recorded and summarized. To assess the effectiveness of En-DCR therapy, both anatomical and functional success rate was assessed during a 12mo follow-up.

Results: A total of 141 patients, with a mean age of 57.70±14.11y, were enrolled in this study. Majority of the patients were female (n=91; 64.54%) and all had unilateral disease. All patients had a previous history of epiphora and purulent secretion, and the duration from lacrimal duct obstruction to mucocele formation ranged from 6 to 120mo. MRI findings consistently revealed an enlarged sac diameter, fluid accumulation separated by a thin rim from adjacent tissues, which is indicative of lacrimal sac mucocele. En-DCR was performed with an anatomical success rate of 93.62% and a functional success rate of 81.56%.

Conclusion: ALSM is more commonly seen in females and unilaterally. It is essentially a complication of lacrimal duct obstruction. MRI characteristics can be used for precise clinical diagnosis, while En-DCR emerges as an optimal therapy for this condition. Our results provide a comprehensive reference for the diagnosis and treatment of ALSM.

查看原文本刊更多论文

内窥镜泪囊鼻腔造口术治疗获得性泪囊黏液囊肿141例。

目的：探讨获得性泪囊黏液囊肿（ALSM）患者的临床特点，评价内镜下泪囊鼻腔造瘘术（En-DCR）治疗此病的疗效。方法：2016年1月至2022年3月对141例ALSM患者进行en - dcr。记录和总结临床基线信息和磁共振成像（MRI）图像。为了评估En-DCR治疗的有效性，在12个月的随访期间评估解剖和功能成功率。结果：141例患者入组，平均年龄57.70±14.11岁。大多数患者为女性(n=91；64.54%)，均为单侧病变。所有患者既往均有泪显及脓性分泌物病史，从泪管梗阻到粘液囊肿形成的时间为6 ~ 120mo。MRI结果一致显示泪囊直径增大，与邻近组织隔有一薄边缘的积液，提示泪囊黏液囊肿。En-DCR的解剖成功率为93.62%，功能成功率为81.56%。结论：ALSM多见于女性和单侧。它本质上是泪管阻塞的并发症。MRI特征可用于精确的临床诊断，而En-DCR则是该病症的最佳治疗方法。我们的结果为ALSM的诊断和治疗提供了全面的参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of ophthalmology Medicine-Ophthalmology

CiteScore

2.50

自引率

7.10%

发文量

3141

审稿时长

4-8 weeks

期刊介绍： · International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online). This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed, PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166. IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO); Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President, Chinese Academy of Engineering. International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of AAO/PAAO) et al. Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society). Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press). Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics). Associate Editors-in-Chief include: Prof. Ning-Li Wang (President Elect of APAO); Prof. Ke Yao (President of Chinese Ophthalmological Society) ; Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ; Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA); Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society); Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA); Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA). IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles, both basic and clinical papers. Instruction is Welcome Contribution is Welcome Citation is Welcome Cooperation organization International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.